{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.9","upperLimit":"1.0","value":"1.0"},{"groupId":"OG001","lowerLimit":"0.9","upperLimit":"1.0","value":"1.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"115"}],"units":"Participants"}],"description":"TTR is the time between date of CTL019 infusion until first documented response (CR or PR).","dispersionType":"95% Confidence Interval","groups":[{"description":"Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who received tisagenlecleucel manufactured at the Novartis manufacturing facility in Morris Plains, US.","id":"OG000","title":"Tisagenlecleucel - Main Cohort"},{"description":"Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who received tisagenlecleucel manufactured at the Novartis manufacturing facility in Morris Plains, US and at the Fraunhofer Institut für Zelltherapie, Leipzig, Germany.","id":"OG001","title":"Tisagenlecleucel - All Patients"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set (FAS): Comprised all patients in the Main cohort who received infusion of tisagenlecleucel.","reportingStatus":"POSTED","timeFrame":"up to approx. 3.3 months","title":"Time to Response (TTR) as Assessed by Independent Review Committee (Main Cohort & All Patients)","type":"SECONDARY","unitOfMeasure":"Months"}